EMA Suspended: Oxbryta (voxelotor) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA has suspended the EU marketing authorization for Oxbryta (voxelotor) by Pfizer Europe MA EEIG, affecting its use for sickle cell disease and related ane…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Hemolytic Anemia
• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Status: Suspended. Therapeutic area: Anemia;Anemia, Hemolytic;Anemia, Sickle Cell. MAH: Pfizer Europe MA EEIG. Decision date: 17/05/2024. Orphan medicine